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A B S T R A C T
Introduction: Hepatic glycogen storage diseases (GSDs) are a group of inherited disorders of carbohydrate me-
tabolism for which dietary management is the cornerstone. Safety and acute complications associated with
dietary management have been poorly documented. We hypothesized that safety issues and complications as-
sociated with dietary management are prevalent amongst patients with these ultra-rare disorders.
Methods: A questionnaire was developed consisting of 40 questions and was distributed via eight GSD patient
organizations from multiple countries. Respondents were (caregivers of) patients with self-reported hepatic GSD.
Results: 249 GSD patients from 26 countries responded with a median age of 14.8 years (range: 0.5–66.1).
Although management was considered safe by 71% of patients, 51% reported at least one acute complication
associated with dietary management, with a total number of 425 reported complications.
Most frequently reported causes were: not waking up by an alarm clock (n= 70), forgetting a meal (n=57)
and infections (n=43). Most frequently reported complications were: hypoglycemia (n= 112), hospital ad-
missions (n=79) and drowsiness (n=74). Most complications occurred before the age of 12 years (82%; 637/
774 total number of reported events) and during night time (63%; 340/536). Only 61% (152/249) of the GSD
patients reported using a written emergency protocol.
Conclusions: Safety issues and complications associated with dietary management are prevalently reported by
(caregivers of) 249 GSD patients. A discrepancy has been observed between the patient's perspective on safety of
dietary management and occurrence of complications as a result of dietary management.
1. Introduction
Hepatic glycogen storage diseases (GSDs) are a group of inherited
disorders of carbohydrate metabolism resulting from an enzyme or
transporter deﬁciency in the glycogen synthesis or breakdown. Clinical
presentation is characterized by fasting hypoglycemia, failure to thrive,
and hepatomegaly [1]. Dietary management is the cornerstone of
therapy, which may include frequent feeds, continuous nocturnal gas-
tric drip feeding (CNGDF) and/or uncooked cornstarch (UCCS). The
introduction of dietary management has changed the prognosis of pa-
tients with several subtypes of GSDs from fatal into manageable dis-
eases [2–5]. The general purpose/aim of dietary management in GSD
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patients is to maintain normoglycemia, preventing secondary metabolic
derangement and development of long-term complications, such as
hepatocellular adenomas/carcinomas, (cardio) myopathy, renal failure
and osteoporosis [6].
Despite improved dietary management for GSD patients, case re-
ports have described fatal outcomes after technical and/or personal
failures. Fernandes et al. has emphasized the necessity of a safety device
in case of inadvertent placement of nasogastric tubes [3]. Both the
European and American guidelines have acknowledged the importance
of safety precautions, such as bed-wetting devices (to detect formula
leakage), feeding pump alarms, tape, adapters, connectors and emer-
gency protocols [6–8]. However. these previous studies have not been
designed to systematically investigate dietary management associated
safety issues.
Based on our experiences in our doctor's oﬃces, we have hypothe-
sized that safety issues and acute complications associated with dietary
management are underreported and relatively common amongst GSD-
patients. This information provides an extra dimension to discussions
on reimbursement of medical devices and nursing support at home for
(caregivers of) GSD-patients. Therefore, we aimed to assess the pre-
valence and the potential consequences of dietary complications and
technical failures in patients with hepatic GSD.A questionnaire was
developed and distributed with the support of eight international GSD
patient organizations.
2. Methods
The Medical Ethical Committee (METc) of the University Medical
Center Groningen stated that the Medical Research Involving Human
Subjects Act (WMO) did not apply to this project and that an oﬃcial
review and approval of this study was not required (METc 2015/522).
2.1. Patients
Respondents were (caregivers of) patients with self-reported hepatic
GSD. We excluded multiple entries by the same responder. GSD patients
above the age of twelve years were invited to answer the questionnaire
together with the caretaker/parent. Caretakers and/or parents were
requested to ﬁll in the questionnaire for patients below the age of
twelve.
2.2. Questionnaire development
A focus group was composed consisting of health care providers,
patients and carers, representing international patient organizations to
draft, translate and distribute a SurveyMonkey® web-based ques-
tionnaire. The group included authors of this manuscript and the per-
sons mentioned in the acknowledgements section. The questionnaire
consisted of 40 questions on ﬁve pages in three distinctive segments:
personal information, dietary management and complications (see
supplementary material for the English version).
2.3. Questionnaire distribution
The ﬁnal English version was translated by native speakers and
distributed in the following languages: Dutch, English, French, German,
Portuguese, and Spanish. Comments were translated via reverse trans-
lation. The questionnaire was distributed through social media by the
following eight patient organizations: Association for Glycogen Storage
Disease (AGSD, USA), Association for Glycogen Storage Disease – UK
(AGSD-UK), Canadian Association for Glycogen Storage Disease
(Canada), Glucolatino (Latin America), Associação Brasileira de
Glicogenose (ABGLICO, Brazil), Selbsthilfegruppe Glykogenose
Deutschland e.V (SHG Glykogenose, Germany), Scandinavian
Association for Glycogen Storage Disease (SAGSD, Scandinavia) and
Volwassen Kinderen en Stofwisselingsziekten (VKS, The Netherlands).
The questionnaire was distributed on 15-03-2016 and closed on 25-07-
2016, with a reminder sent on 10-07-2016.
2.4. Data analysis
In data analysis, acute complications were deﬁned as either drow-
siness and/or hypoglycemia. Severe complications were deﬁned as
those conditions, that would correspond with the deﬁnition of serious
adverse events [9], including hospital admission, intensive care unit
admission, seizures/epilepsy, coma and/or death.
2.5. Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics for
Windows v23.0 (Armonk, NY: IBM Corp.) and Microsoft Excel
v.14.0.4734.1000 for Windows (Microsoft Corp., Redmond, WA, USA).
Based on the sample size, the Kolmogorov-Smirnov test was used to test
for normality. Since the data was not normally distributed, non-para-
metric tests were performed to examine diﬀerences between groups.
For diﬀerences between groups, the Chi-Square test or Kruskal-Wallis
test was performed, where appropriate. Diﬀerences were considered
statistically signiﬁcant at p < 0.05.
3. Results
In total 249 GSD patients from 26 countries responded, whose
general characteristics are presented in Table 1. Mean age was
14.8 years (range: 0.5–66.1), 64% (159/249; 1 non-responders) of the
patients were diagnosed before one year of age. Although management
was considered safe by 71% (178/249) of patients, 52% (n= 129) re-
ported at least one acute complication associated with dietary man-
agement. A total number of 425 complications was reported, including
364 severe complications. In Table 2, the complications and safety is-
sues associated with dietary treatment are stratiﬁed by GSD subtype.
Table 3 presents the frequence of reported complications associated
with the dietary management on a monthly basis (referring to question
26). Most frequently reported causes were: not waking up by an alarm
clock (n=70), forgetting a meal (n=57) and infections (n= 43). In
question 30, of the 129 patients reporting complications, most fre-
quently reported were: hypoglycemia (n= 112), hospital admissions
(n= 79) and drowsiness (n= 74). Less frequent complications were:
ambulance called (n= 57), seizures/epilepsy (n= 47), intensive care
unit admissions (n=39) and coma (n=17). In Question 31, the pa-
tients were asked to report the complications and the corresponding age
at which the complications occurred. Most complications occurred be-
fore the age of 12 years (82%; 637/774 total number of reported
events) and during night time (63%; 340/536). Fig. 1 shows the dif-
ferent age groups and their corresponding number and type of com-
plications.
Only 61% (152/249) of the GSD patients reported using a written
emergency protocol during intercurrent illness. Interestingly, patients
with an emergency protocol had statistically more complications than
patients without an emergency protocol (chi-square; p < 0.001). In
this study, 17% of the patients did not have a glucose meter and an
additional 14% of the patients did not use it. Of patients, 47% actively
set an alarm and 5% reported using a bed wetting device to detect
detached continuous feeds.
In Question 33, the patients were asked ‘What was consequence of
the severest complication?’. In total, 30% (43/142 total number of re-
ported events) were managed at home, 46% required hospitalization,
whereas intensive care unit admission and resuscitation were required
in 18% and 5%, respectively.
Table 4 displays qualitative comments of (caregivers/parents of)
GSD patients, illustrating the burden of the disease.
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4. Discussion
Following previous case reports [10, 11], this is the ﬁrst study of
patient reported outcomes on safety issues associated with dietary
management in a large cohort of GSD patients.
The majority of the total number of reported complications (82%)
manifested before the age of twelve. Within this age group most events
have been reported by caregivers of patients between 1 and 4 years of
age (45%) and 4–12 years of age (31%). Several factors may complicate
hypoglycemia awareness in young GSD patients. Young children are
limited in communication and may be more vulnerable for both in-
fections and their relatively high endogenous glucose requirements, the
latter may ﬂuctuate due to unpredictability in physical activity. Besides
limitations in communication in preverbal children, compared to
adults, children more often present with behavioral diﬀerences during
hypoglycemia [12, 13]. In GSD I patients, hypoglycemia awareness may
be aﬀected by suppression of neuroglycopenic symptoms and signs, by
the brain using lactate as an alternative source of energy [14].
Most complications (63%) occurred at night resulting from human
errors which theoretically are preventable (e.g. forgetting a meal, for-
getting to switch on the pump, misplacement of a tube and problems
associated with an alarm clock). This indicates a potential hazardous
timeframe, illustrating the necessity of safety measures to guarantee
safety of the patient at night. In addition, this study indicates that pa-
tients (and caregivers) may have a distorted safety perception and may
therefore not be aware of the potential hazards of dietary management.
Systematic check-ups by the caregiver/parent and increasing the
availability of devices (such as alarming subcutaneous Continuous
Glucose Monitors (CGM)) are important preventive measures to in-
crease safety.
In line with previous reports [2, 10], the comments of the re-
spondents in this study highlight the burden associated with the intense
dietary management (Table 4). It has been described that GSD patients
report a lower quality of life than healthy controls [15]. Additionally, a
signiﬁcant severity of distress amongst the caretaking parents is re-
ported. GSD patients require a time-intensive dietary management with
continuous vigilance, as fasting tolerance is severely aﬀected and blood
glucose concentrations drop within minutes. The constant fear of hy-
poglycemia can be stressful for patients and their families and the re-
sulting exhaustion brings an increased risk of developing complications
[5]. Therefore, safety precautions with the aim to prevent hypogly-
cemia and increase awareness of hypoglycemic symptoms could po-
tentially contribute in reducing disease burden for both the patient and
caregiver.
Besides alarm clocks, bed wetting devices and hand devices to
monitor blood glucose concentrations, there is increasing experience
with the use of subcutaneous CGM-meters in GSD patients [16–19],
such as recent introduction of the Freestyle Libre [20]. The newest
generation of CGM devices support real-time following and alarming to
caregivers, which could be beneﬁcial in preventing and detecting hy-
poglycemia. Moreover, the technology would increase the opportunities
of families to immediately check the glucose concentrations at any
given moment in time. This provides the possibility to detect hazardous
moments such as nocturnal- and severe asymptomatic hypoglycemia
and hypoglycemia in preverbal children, implementing an additional
layer of safety and creates opportunities to recognize ﬂuctuations for
optimizing regimens. These advantages should obviously be balanced
against the potential disadvantages, such as medicalization, technical
failures by these devices, measurements of non-severe (asymptomatic)
hypoglycemia and possible interference of organic compounds (e.g. uric
acid and lactate).
Of the patients included in this study, 61% used an emergency
protocol. Interestingly, patients with an emergency protocol had sig-
niﬁcantly more complications. Likely, respondents reﬂect the well-in-
formed patient community, who are better prepared with emergency
protocols. However, in some situations in more severely aﬀected pa-
tients, experienced complications may have preceded health care pro-
fessionals to provide an emergency protocol. Emergency protocols are
in theory a beneﬁcial safety measure, as the immediate correct treat-
ment may be delayed by health care providers due to the unfamiliarity
of these complex and rare diseases. Longitudinal data on the eﬀec-
tiveness of emergency protocols is warranted.
There is a gap between disease guidelines for cohorts of patients and
individual patient care plans. Similar to GSD patients, patients with
Diabetes Mellitus (DM) are also vulnerable to nocturnal hypoglycemia.
Inadequate amount of hepatic glycogen in insulin-deﬁcient diabetes
patient increases the risk of nocturnal hypoglycemia [21]. However, in
contrast to GSD patients, DM patients have (age-speciﬁc) guidelines and
recommendations providing information regarding the safety, admin-
istration, pitfalls of their management [22, 23]. Recommendations for
optimal metabolic control by dietary management of GSD I and GSD III
patients are available in guidelines [6, 7, 24, 25]. However, these
guidelines describe large cohorts and do not focus on individual pa-
tients. Additionally, the safety outcomes of dietary management and
prevention of acute complications are neither discussed nor mentioned,
and is overall rarely found in literature. A recent study of our center
Table 1
Characteristics of (caregivers representing) GSD patients (referring to questions 2, 4 and 5).
GSD Type Type 0 Type Ia Type Ib Type IIIa Type IIIb Type IV Type VI Type IX Type XI Unknown N.R. Total
n 3/249 134/249 39/249 17/249 5/249 1/249 3/249 23/249 2/249 17/249 5/249 249
(1%) (54%) (16%) (7%) (2%) (0,4%) (1%) (9%) (0,8%) (7%) (2%)
Male % 33% 44% 47% 47% 20% 100% 33% 63% 50% 68%
Country of Origin 226c
The Netherlands – 3 – 3 – – – 3 1 – 10 (4%)
Germany – 39 14 1 – – – 2 – – 56 (22%)
Sweden – – 2 – – – – – – – 2 (1%)
Finland – – – 2 – – – – – – 2 (1%)
Brazil – 31 8 3 1 – – 1 – 8 2 54 (22%)
UK – – – 1 1 – 1 – – – 1 4 (2%)
USA 3 32 6 3 – – 1 10 1 3 59 (24%)
Norway – – – 2 1 – 1 2 – – 6 (2%)
Denmark – 7 – – – – – – – 1 8 (3%)
Canada – 8 7 – 2 1 – 4 – – 22 (9%)
Othera – 12 2 2 – – – 1 – 4 21 (8%)
N.R. – 2 – – – – – – – 1 2 5 (2%)
N.R. is deﬁned as Not Responded and indicates responders who did not answer the question. Unknown indicates responders who answered they did not know the
GSD type. a= Patients were asked to choose their country of origin out of the countries speciﬁed in the table options (n=226). 8% of responders indicated to
originate from the following 16 countries (n=21): Algeria (1), Australia (1), Bahamas (1), Chile (1), Croatia (2), France (1), Greece (2), Guatemala (1), India (2),
Mexico (1), Pakistan (2), Poland (1), Russia (1), Spain (2), Switzerland (1), Yemen (1).
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focused on heterogeneity between GSD Ia patients. This study states
that there is no clear deﬁnition of good metabolic control and empha-
sized the need for an individualized approach to dietary management
for GSD Ia patients [26]. Along with the complexity of GSD, the paper
by Shah and O'Dell, and the published commentary of Derks et al.
highlights the diﬃculties in dietary management of GSD patients and
emphasizes the lack of information of long-term follow-up data [27,
28]. Therefore, acquiring disease speciﬁc patient derived big data by
developing a registry could be beneﬁcial in terms of safety- and treat-
ment measures for both the medical healthcare professional as for the
patient. These developments will be important stepping stones in pa-
tient-centered health care for which several legal and technical chal-
lenges need to be bridged.
Some methodological issues of our patient centered study need to be
addressed. First, our questionnaire was designed to make an inventory
of patient reported outcomes on safety in general, rather than to com-
pare the safety situations between patients of diﬀerent GSD subtypes or
diﬀerences between dietary managements. Unfortunately, the anon-
ymous data provided by patients could not be double checked by the
treatment center of the patient, hence the genetic diagnosis could not
be conﬁrmed. We cannot completely exclude that a subset of the re-
spondents who reported an unknown type of GSD may suﬀer from an
alternative diagnosis. Our data on safety related to complex dietary
treatment, however, presents a unique perspective from the patient's
point of view and is further supported by the high number of re-
sponders. Secondly, this study has been impacted by ascertainment
bias, towards relatively well-informed individuals, who engage with
patient organizations and/or social media. Response rate could not be
determined as the distribution did not allow to indicate the denomi-
nator from which the sample size was drawn. Therefore, one can only
speculate how the distribution of the questionnaire has aﬀected the
results of this study. Respondents may have been overrepresented by
severe cases, due to unreachability or unresponsiveness of milder pa-
tients. On the contrary, responses about deceased GSD-patients may
have been underrepresented too.
Nevertheless, this is the ﬁrst ever study of its kind on safety issues
related to dietary management of GSD patients and it is of interest to
health care providers, patients, caregivers and health care policy ma-
kers who shape future health care. Dietary management for hepatic
GSD-patients is complex for many reasons, including the complexity of
the disease and fast variations in glucose homeostasis, non-compliance
with glucose monitoring and problems of reimbursement of medical
devices (like traditional blood glucose/ketone monitors, continuous
glucose monitors) and home care. The questionnaire could be applied
prospectively in collaborating centers to provide a denominator and
more comprehensive data collection, ideally in web-based applications
connected with hospital based electronic patient ﬁles [29].
As some complications would fulﬁll the deﬁnition of serious adverse
events, safety assessment for medically prescribed diets in patients with
inherited metabolic diseases deserve the same level of awareness and
safety assessment compared to (the prescription of) regular medicines.
We report a high prevalence of safety issues and complications as-
sociated with dietary treatment in hepatic GSD-patients, especially
amongst the youngest patients and at night. This information provides
an important dimension in discussions on reimbursement of medical
devices and nursing support at home for (caregivers of) GSD-patients.
Ideally, safety outcomes should be integrated in communications on
patient reported outcome measures and patient reported experience
measures [30]. The application of modiﬁed FAIR (ﬁndability, accessi-
bility, interoperability, and reusability) guiding principles is beyond
scientiﬁc data management but will be a crucial precondition for health
care data management, especially for patients with ultra-rare diseases.
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